Frontlight ResearchEarly access
Taking peoplePhase 3
Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial (ASPRE-T)
Key facts
- Who runs it
- Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
- Where
- Austria, Belgium, Bulgaria, Czechia, Denmark, Greece, and Spain19 sites in 7 countriesChoose a country to see its sites
- Trial code
- EU 2023-503698-40-00
- EudraCT 2019-003341-15
- ISRCTN86684235
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,298 people, planned
- Started
- 23 Mar 2023
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 27 August 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age > 18 years
- DCDA or MCDA twin pregnancies
- Both live fetuses at 11+2-13+6 weeks of gestation
- Informed and written consent
Who cannot take part
- Patients on long term non-steroidal anti-inflammatory medication
- Women taking low-dose aspirin regularly (administration must have ceased >7 days prior to randomization)
- Participation in another drug trial within the previous 7 days
- Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia or concurrent anticoagulant therapy
- Patients who are suffering from known gout, severe hepatic impairment or severe renal impairment
- Hypersensitivity to salicylic acid compounds or prostaglandin synthetase inhibitors (e.g. certain asthma patients who may suffer an attack or faint and certain patients who may suffer from bronchospasm, rhinitis and urticaria) or to any excipients (see section 6.1 of the SmPC for details)
- Active or history of recurrent peptic ulceration and/or gastric/intestinal haemorrhage, or other kinds of bleeding such as cerebrovascular haemorrhages
- Monoamniotic twins
- Not fluent in local language and absence of interpreter
- Any other reason the clinical investigators think will prevent the potential participant from complying with the trial protocol
- Triplet pregnancies that had undergone embryo reduction to twins or with one vanishing twin
- Pregnancies complicated by major fetal abnormality or nuchal translucency thickness >3.5 mm identified at the 11+2-13+6 weeks scan
- MCDA twin pregnancies in which there are early signs of TTTS or sFGR defined by a 20% discordance in CRL at the 11+2-13+6 weeks’ scan
- Those who lack capacity and who are unable to provide informed consent to take part
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial is currently available in Austria, Belgium, Bulgaria, and 4 more countries.
It has sites in 7 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To determine the effect of low-dose aspirin on theincidence of preterm preeclampsiawith delivery <37 weeks’ gestation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial (ASPRE-T)
- Criteria questions
- Built from 2023-503698-40-00, who can take part
- Record updated
- 27 August 2026